The results clearly indicate that semaglutide 2.4 mg is superior to tirzepatide in reducing cardiovascular events in individuals with overweight or obesity
Listing language should stay focused on research use, compound identity, analytical testing, and documentation
James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW: Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism
Based on class effects observed with approved agents and general clinical reasoning, certain patient groups may warrant closer monitoring during any future clinical use of retatrutide